These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1458882)

  • 1. Once-daily aminoglycosides.
    Nicolau D; Quintiliani R; Nightingale CH
    Conn Med; 1992 Oct; 56(10):561-3. PubMed ID: 1458882
    [No Abstract]   [Full Text] [Related]  

  • 2. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
    Vandenbussche HL; Klepser ME
    Lancet; 2005 Feb 12-18; 365(9459):547-8. PubMed ID: 15708080
    [No Abstract]   [Full Text] [Related]  

  • 3. Once-daily versus pharmacokinetic dosing of aminoglycosides.
    Medicus-Bringa M; Ward G; Rice M
    Am J Med; 1997 Oct; 103(4):328-30. PubMed ID: 9382126
    [No Abstract]   [Full Text] [Related]  

  • 4. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic bone cement for the treatment of Pseudomonas aeruginosa in joint arthroplasty: comparison of tobramycin and gentamicin-loaded cements.
    Scott CP; Higham PA
    J Biomed Mater Res B Appl Biomater; 2003 Feb; 64(2):94-8. PubMed ID: 12516083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs.
    Prober CG; Walson PD; Jones J
    Pediatrics; 2000 Dec; 106(6):E89. PubMed ID: 11099632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Once-daily" versus "extended-interval" administration of aminoglycosides in neonates: need for standard terminology.
    Miller MM; Burton ME; Johnson PN; Miller JL
    Am J Health Syst Pharm; 2014 Dec; 71(24):2108-9. PubMed ID: 25465576
    [No Abstract]   [Full Text] [Related]  

  • 8. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
    Zelenitsky SA; Karlowsky JA; Hoban DJ; Kabani A; Zhanel GG
    Chemotherapy; 1998; 44(1):1-6. PubMed ID: 9444401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections.
    Van Eldere J
    J Antimicrob Chemother; 2003 Feb; 51(2):347-52. PubMed ID: 12562701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimizing the toxicity of aminoglycosides in cystic fibrosis.
    Smyth AR
    J R Soc Med; 2010 Jul; 103 Suppl 1(Suppl 1):S3-5. PubMed ID: 20573667
    [No Abstract]   [Full Text] [Related]  

  • 11. Appropriate comparators for alternate dosing strategies.
    Tucker H; Wu D
    Clin Infect Dis; 2007 Jul; 45(2):269; author reply 269-70. PubMed ID: 17578793
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of the postantibiotic effect and postantibiotic sub-MICs effect of netilmicin, tobramycin, ciprofloxacin and pefloxacin on alginate production by Pseudomonas aeruginosa.
    Majtán V; Hostacká A
    Folia Microbiol (Praha); 1996; 41(3):228-32. PubMed ID: 9449771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and side-effects of gentamicin in healthy and pseudomonas aeruginosa infected sheep.
    Lashev L; Lasarova S
    J Vet Pharmacol Ther; 2001 Jun; 24(3):237-40. PubMed ID: 11442805
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa.
    Cardozo C; Rico V; Agüero D; Soriano A
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 2(Suppl 2):32-34. PubMed ID: 31475807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis.
    Sherwin CM; Zobell JT; Stockmann C; McCrory BE; Wisdom M; Young DC; Olson J; Ampofo K; Spigarelli MG
    J Pharmacokinet Pharmacodyn; 2014 Feb; 41(1):71-9. PubMed ID: 24395072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A long-term study of gentamicin-resistant Pseudomonas aeruginosa in a general hospital.
    Duncan IB; Rennie RP; Duncan NH
    J Antimicrob Chemother; 1981 Feb; 7(2):147-55. PubMed ID: 6783608
    [No Abstract]   [Full Text] [Related]  

  • 18. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
    Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
    Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.